



THOMPSON STREET CAPITAL PARTNERS ACQUIRES LIFESPAN BIOSCIENCES, INC.

ST. LOUIS (September 17, 2018) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, has partnered with management to acquire Seattle-based LifeSpan Biosciences, Inc., (LSBio). The Company is a founder-led developer and distributor of antibodies and related reagents primarily to the academic and pharmaceutical research markets via its e-commerce platform. Terms of the transaction were not disclosed.

LSBio (www.lsbio.com), originally founded as an immunohistochemistry (IHC) services provider in 1995, has evolved to offer a broad range of antibodies, kits, proteins and other biological reagents. The Company's offerings include proprietary, value-added and third-party products. Researchers have long relied upon LSBio's expertise to fulfill their molecular pathology needs. As part of its growth strategy, the Company plans to continue expanding its catalog of high-quality reagents, both through internal research and development and a targeted acquisition strategy.

Bob Dunn, a Managing Director and Head of Acquisitions at TSCP, said, "We're excited to be partnering with the founders of LSBio. The Company fills a highly specific niche in its industry and enjoys a well-deserved reputation for excellence, innovation and customer service. LSBio's ongoing mission is to expand upon its capabilities to provide the vital materials necessary for fueling important scientific research. We're proud to help facilitate the ongoing growth of LifeSpan Biosciences."

BroadOak Capital Partners served as LifeSpan Biosciences' exclusive financial adviser. Achelous Partners acted as Thompson Street's financial adviser.

###